AMARIN CORP PLC\UK — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AMARIN CORP PLC\UK filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $181.10M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $130.08M | Feb 27, 2018 |
| FY2017 | Dec 31, 2015 | $81.76M | Feb 27, 2018 |
| FY2014 | Dec 31, 2014 | $16.48M | Mar 3, 2015 |
| FY2014 | Sep 30, 2014 | $14.15M | Mar 3, 2015 |
| FY2014 | Jun 30, 2014 | $12.61M | Mar 3, 2015 |
| FY2014 | Mar 31, 2014 | $10.97M | Mar 3, 2015 |
| FY2014 | Dec 31, 2013 | $10.11M | Mar 3, 2015 |
| FY2014 | Sep 30, 2013 | $8.40M | Mar 3, 2015 |
| FY2014 | Jun 30, 2013 | $5.50M | Mar 3, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $213.65M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $228.61M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $306.91M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $369.19M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $583.19M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $614.06M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $143.28M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $112.41M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $100.79M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $73.28M | Feb 25, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $53.87M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $47.36M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $45.24M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $34.64M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $38.70M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $32.73M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $33.11M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $25.54M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $26.63M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $21.48M | Mar 1, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $81.38M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $165.54M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $242.48M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $461.86M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $482.62M | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $112.61M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $86.96M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $78.02M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $56.14M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.80M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($82.18M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($59.11M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($105.80M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $7.73M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($18.00M) | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | $7.07M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | ($3.46M) | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | ($1.82M) | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | ($24.43M) | Feb 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($50.17M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($91.80M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($67.59M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($105.87M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $10.50M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($19.66M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($24.28M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($108.23M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($45.56M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($65.63M) | Feb 27, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.81M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $20.87M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $22.22M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $30.41M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $29.31M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $38.96M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $34.39M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $55.90M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $47.16M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $49.98M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.00M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $152.31M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $199.94M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $304.42M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $408.33M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $463.31M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $323.62M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $227.00M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $134.55M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $111.37M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.73M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($31.02M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $6.88M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($180.09M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($66.54M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($21.75M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($9.37M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($94.70M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($32.84M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($71.82M) | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $252.0K | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $2.48M | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $58.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $12.0K | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $21.0K | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $28.0K | Feb 27, 2018 |
| FY2015 | Dec 31, 2013 | $14.0K | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $549.0K | Mar 3, 2015 |
| FY2013 | Dec 31, 2011 | $398.0K | Feb 27, 2014 |
| FY2012 | Dec 31, 2010 | $23.0K | Feb 28, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $670.78M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $685.35M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $831.68M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $886.18M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.07B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $966.02M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $882.21M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $385.71M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $161.60M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $167.00M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $211.49M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $199.17M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $279.59M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $290.85M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $400.97M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $338.52M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $273.95M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $233.38M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $226.70M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $176.06M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $459.28M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $486.18M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $552.10M | Mar 2, 2026 |
| FY2025 | Dec 31, 2022 | $595.33M | Mar 2, 2026 |
| FY2023 | Dec 31, 2021 | $667.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $627.51M | Mar 1, 2023 |
| FY2022 | Dec 31, 2019 | $608.26M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $152.33M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | ($65.10M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | ($9.06M) | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.71B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($1.67B) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($1.59B) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($1.53B) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($1.42B) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($1.43B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.41B) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.39B) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($1.27B) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($1.20B) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.66M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $121.04M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $199.25M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $217.67M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $219.45M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $186.96M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $644.59M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $249.23M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $73.64M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $98.25M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2019 | $49.70M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $79.71M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $92.40M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $93.59M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $91.51M | Mar 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Feb 25, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 416.21M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 411.58M | Mar 2, 2026 |
| FY2023 | Dec 31, 2023 | 408.82M | Feb 29, 2024 |
| FY2024 | Dec 31, 2022 | 408.82M | Mar 12, 2025 |
| FY2022 | Dec 31, 2021 | 396.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 392.54M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 360.10M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 325.85M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 271.02M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 269.36M | Feb 27, 2018 |